2 July 2021 in Science Advances
MDMaria Cristina Huertas Diaz
Maria Cristina Huertas Diaz
+14
Single-dose intranasal COVID-19 vaccine prevents infection and inhibits transmission.
12 September 2025 in Science Advances
Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e). Combined at low dose, this “triple M2e-mAb” confers robust prophylactic and therapeutic protection in mice challenged with diverse human and zoonotic IAV strains, including highly pathogenic variants. Therapeutic efficacy depends on Fc-mediated effector activity via FcγRI, FcγRIII, and FcγRIV, rather than in vitro neutralization. Serial passaging in triple M2e-mAb–treated immunocompetent and immunodeficient hosts failed to generate viral escape mutants. Our findings redefine the influenza-specific antibody therapeutic design and support Fc-optimized, non-neutralizing M2e-mAbs as a broadly effective, mutation-resistant, off-the-shelve therapy with direct relevance to human pandemic preparedness.
31 July 2026 in SSRN Electronic Journal
Live Attenuated Influenza Vaccines (LAIV) are attenuated, temperature sensitive, and cold adapted to limit replication to the upper respiratory tract. This modification seeks to prevent clinical disease while effectively eliciting the development of immunity. While LAIVs offer benefits over Inactivated Influenza Vaccines (IIV), thermostability remains a key concern. Using Preservation By Vaporization (PBV), we have established a thermostable LAIV (tLAIV) that is stable at ambient temperature for at least one year and suitable for respiratory delivery in a dry powder form. Using the ferret model, we have demonstrated that tLAIV elicited protective immune responses to subsequent influenza virus infection. Here, we expand on these studies to confirm the safety of tLAIV following intranasal administration. Continuing with the ferret model, we completed a dose-response safety and immunogenicity study of tLAIV formulated both with and without Advax adjuvant and compared the results to those of liquid LAIV controls. Dry-powder vaccination with tLAIV or LAIV did not cause significant temperature elevations, lethargy, weight loss, or other clinical changes. Clinical chemistry and complete blood counts (CBC) remained within established baseline reference ranges. On histopathology, there were no adverse effects seen on the upper or lower respiratory tract 14 days after vaccine delivery. ELISA and hemagglutination inhibition assays (HAI) confirmed seroconversion was induced by all vaccine formulations, with neither dose nor adjuvant improving the magnitude of response. Nasal wash analysis demonstrated that PBV- stabilized tLAIV exhibited comparable infectivity to the same dose of liquid LAIV control. These findings further reinforce the similarity in infectivity, immunogenicity, and safety of intranasal vaccination using PBV-tLAIV, both with and without an adjuvant.